Drug interactions
Lapatinib + Suvorexant
Severity: Minor
Lapatinib and Suvorexant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lapatinib, a weak CYP3A4 inhibitor, may increase suvorexant exposure. This can cause greater next-day sedation, somnolence and impaired driving.
What this interaction means in plain words
Lapatinib and Suvorexant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Lapatinib belongs to Oncology; Suvorexant belongs to Central Nervous System.
Why it happens
Lapatinib inhibits CYP3A4, the main enzyme metabolizing suvorexant.
What to do
Use the lowest effective suvorexant dose and warn the patient about next-day drowsiness. Reduce the dose if excessive sedation occurs.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lapatinib and Suvorexant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Other interactions of Suvorexant
Frequently asked questions
Can I take Lapatinib with Suvorexant?
MediHelp rates the interaction as minor. Lapatinib and Suvorexant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lapatinib, a weak CYP3A4 inhibitor, may increase suvorexant exposure. This can cause greater next-day sedation, somnolence and impaired driving.
How serious is the interaction between Lapatinib and Suvorexant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use the lowest effective suvorexant dose and warn the patient about next-day drowsiness. Reduce the dose if excessive sedation occurs.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
